Close

Cardiff Oncology (CRDF) Reports Onvansertib Phase 1b/2 Data Demonstrates Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. TSM
2. NFLX
3. LVS
4. SPY
5. INFY
6. CSX
7. UAL
8. TSLA
9. NVDA
10. ALK


Go back to Cardiff Oncology (CRDF) Reports Onvansertib Phase 1b/2 Data Demonstrates Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC
(NASDAQ: CRDF) Delayed: 4.37 -0.13 (2.89%)
Previous Close $4.50    52 Week High $ 
Open $4.43    52 Week Low $ 
Day High $4.48    P/E N/A 
Day Low $4.26    EPS $ 
Volume 832,011